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Background: Global and regional economic and political plat-
forms like the Group of 7 (G7) and the Association of Southeast
Asian Nations (ASEAN) and development banks like the Inter-
American Development Bank (IDB) and the World Bank, are
increasingly engaged in health and development agenda-setting
and policy guidance. Global economic and political platforms facili-
tate innovative, collaborative partnerships and development banks
offer opportunities to pool resources, knowledge and inﬂuence to
demonstrate greater impact, thereby building support and evi-
dence for these models to be replicated. The Global Network for
Neglected Tropical Diseases (The Global Network) has engaged
with such platforms to push for progress on controlling and elimi-
nating neglected tropical diseases (NTDs).
Methods & Materials: NTDs disproportionately affect the
world’s most socially and economically marginalized populations,
furthering the cycle of poverty and poor health outcomes. Themost
common NTDs, those that effect 1.4 billion people worldwide, are
easily and inexpensively prevented and treated through annual or
biannual mass drug administration. In many cases the drugs are
donated and administration of medication can easily be integrated
into existing health systems. These major barriers have been over-
come, but more can be done to accelerate progress toward WHO’s
2020 NTD control and elimination targets.
Results: Increased energy, political commitment and resources,
and encouraging cross-sectoral and cross-country collaboration
through global policy makers can help to accelerate the progress of
existing country programs, scale the successes across geographic
areas, and mobilize resources.
Conclusion: This presentation will provide examples of global
advocacy and highlight tools that have been helpful in con-
vincing policy makers to take an interest in NTDs, focusing on
increased resource mobilization and opportunities to leverage
existing programs and resources to fund pilot programs and doc-
ument innovative models. Given the entry of new platforms and
funding entities with an interest in health and development, like
the BRICS and the New Development Bank, a review the global
policy advocacy strategies and opportunities is particularly timely.
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Potential impact and economic value of dengue
vaccination in 10 endemic countries
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Background:Withabout100millionapparent infectionsoccur-
ring annually, dengue is a major international public health
concern. To date, no speciﬁc treatment is available for this disease
but the Sanoﬁ Pasteur vaccine candidate has, in 2014, successfully
demonstrated its protective efﬁcacy against symptomatic dengue
in two Phase 3 efﬁcacy trials performed in ﬁve Asian countries
(Indonesia, Malaysia, Philippines, Thailand, Vietnam) and 5 Latin
American countries (Brazil, Colombia, Honduras, Mexico, Puerto
Rico).
Methods & Materials: Results observed during the phase 3 efﬁ-
cacy trials were used to ﬁt an age-structured, host-vector, and
serotype-speciﬁc compartmental model, combined with country-
speciﬁc information on the cost of dengue illness, dengue routine
surveillance data, and population demographics. This model
allowed assessing the potential public health and economic impact
of various vaccination strategies for the 10 countries in these phase
3 trials. The strategies analyzed included routine vaccination alone
(9 year-olds annually) and routine vaccination combined with
alternative catch-up campaigns (targeting from 2 to 20 age cohorts
and completed in 2, 3 or 4 years). The economic value of vacci-
nation programs was assessed from a societal perspective using
WHO criteria for cost-effectiveness, including offsets for medical
costs averted. All costs were expressed in 2015 US$.
Results: Results indicated that 20% to 30% of dengue cases can
be prevented at the population level by using routine vaccination
alone. The combination of routine vaccination and the broadest
catch-up campaigns could reduce the number of dengue cases in
the population over 10 years by 70%. The threshold price per dose
for which vaccination can be considered as cost-effective ranged
from US$20 to US$100 according to country and vaccination strat-
egy considered, or US$60 to US$300 for the 3 recommended doses.
Conclusion: The analysis indicates that the implementation of
dengue vaccination programs has the potential to be cost-effective
in all 10 endemic countries in the Phase 3 efﬁcacy trials.
http://dx.doi.org/10.1016/j.ijid.2016.02.386
